A generic drug manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug.
U.S. Supreme Court. Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, No. 10-844. April 17, 2012. Lawyers USA No. 993-3730.
This is the first edition of Lawyers USA's Lawyers in Practice, where we discuss the hot issues facing practicing attorneys and law firms.
In this edition, we discuss how to prevent legal malpractice claims with better communication, with Jim Calloway, director of the Oklahoma Bar Association's Management Assistance Program, and Dan Pinnington, vice-president of Claims Prevention and Stakeholder Relations at LawPRO, a professional liability carrier based in Toronto, Canada.